Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
VZ$46.75+0.58(+1.26%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.33+0.47(+0.46%)Transaction in Own Shares8:00:53 AM ETISRG$483.40+1.21(+0.25%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETAAPL$354.62+5.11(+1.46%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$217.02+17.56(+8.80%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.25+1.93(+0.76%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETAAPL$354.62+5.11(+1.46%)Apple: Demand Is Not The Problem7:54:50 AM ETMCD$282.00+1.78(+0.64%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.05-4.65(-2.71%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$556.84+1.04(+0.19%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ETQCOM$155.00-18.19(-10.50%)Wall Street Breakfast Podcast: The VIX Plunges In Post-Election Rally7:47:00 AM ETKO$97.10+1.22(+1.27%)If You'd Invested $1,000 Alongside Warren Buffett in Coca-Cola, Here's How Much You'd Have Today7:47:00 AM ETQCOM$155.00-18.19(-10.50%)Qualcomm Q4: This Dip Is Not The One To Buy Yet7:45:04 AM ETAXP$337.65+5.03(+1.51%)American Express vs. PayPal: Which Financial Stock Is a Better Buy for 2027?7:45:01 AM ETSPCX$132.37-3.55(-2.61%)Stack Capital Group Inc. Reports Q3-2026 Financial Results7:45:00 AM ETUBER$72.15+2.25(+3.22%)Amazon and Uber Want to Bring You Your Next Meal. The Delivery Turf War Is Escalating.7:43:00 AM ETCOP$139.45+2.51(+1.83%)BUZZ-ConocoPhillips rises on Q3 profit beat7:40:48 AM ETTGT$165.25+2.20(+1.35%)Target Looks More Attractive Than You'd Think7:31:07 AM ETCOP$139.45+2.51(+1.83%)UPDATE 2-ConocoPhillips beats estimates on higher oil prices, raises dividend7:30:23 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$634.70+4.70(+0.75%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$137.45-0.06(-0.04%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$354.62+5.11(+1.46%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETTSLA$376.34-8.85(-2.30%)Ferrari vs. Tesla: Can the Luce Outsell the Roadster?7:18:00 AM ET

CLYM · NASDAQ

Climb Bio, Inc.

$9.70 +0.37 (+3.97%)

Company overview

Climb Bio, Inc. is a biotechnology company focused on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$557M
Employees
17
Headquarters
Wellesley Hills, DE
Website
eliemtx.com
CEO
Aoife Brennan BCh MMSc
Listed
August 10, 2021
P/E
-12.44
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$106,000
Operating income
-$60.1M
EBITDA
-$55.9M
Net income
-$52.8M
EPS
-$0.78
Total assets
$152M
Total debt
$479,000
Earnings yield
-8.04%

Price chart

8.3110.9113.5216.1218.72
CLYM 1D NASDAQ O9.97H10.10L9.19C9.33-0.42 (-4.31%)Vol882.81K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CLYMClimb Bio, Inc. Stock news Climb Bio Q3 net loss widens as operating expenses rise Reuters
CLYMClimb Bio, Inc. Press release Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire
CLYMClimb Bio, Inc. Press release Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition GlobeNewswire
CLYMClimb Bio, Inc. Press release Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference GlobeNewswire
CLYMClimb Bio, Inc. Press release Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 GlobeNewswire
CLYMClimb Bio, Inc. Press release Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 GlobeNewswire
CLYMClimb Bio, Inc. Stock news Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval Seeking Alpha
CLYMClimb Bio, Inc. Press release Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug GlobeNewswire
HOOD Stock news Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday Benzinga
CLYMClimb Bio, Inc. Stock news Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug MarketBeat
CLYMClimb Bio, Inc. Stock news Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule Benzinga
CLYMClimb Bio, Inc. Press release Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy GlobeNewswire
CLYMClimb Bio, Inc. Press release Climb Bio to Present at Upcoming Investor Conferences GlobeNewswire
CLYMClimb Bio, Inc. Stock news Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility Seeking Alpha
CLYMClimb Bio, Inc. Stock news Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? Zacks Investment Research
CLYMClimb Bio, Inc. Press release Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development GlobeNewswire
CLYMClimb Bio, Inc. Press release Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 GlobeNewswire
CLYMClimb Bio, Inc. Stock news Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect MarketBeat
CLYMClimb Bio, Inc. Press release Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress GlobeNewswire
CLYMClimb Bio, Inc. Press release Climb Bio to Present at Upcoming Investor Conferences GlobeNewswire
See more
FAQ

Questions about Climb Bio, Inc.

What does Climb Bio, Inc. do?
Climb Bio, Inc. is a biotechnology company focused on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
What is CLYM's market cap?
Climb Bio, Inc. (CLYM) is a listed stock with a live quote. The latest market cap on this page is $557M.
Where is Climb Bio, Inc. headquartered?
Climb Bio, Inc. is headquartered in Wellesley Hills, DE.
How do I get CLYM news from the API?
Call GET /v1/news?tickers=CLYM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CLYM news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CLYM, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CLYM price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs